tbuckley/cabot-search huggingface dataset:
Abstract 16469: High Rates of Inappropriate Hypercoagulable State Testing in a Large Clinical Cohort
Authors: Patrick M Kozak, Eric Farber-Eger, Meng Xu, Quinn S Wells, Joshua A Beckman
Journal: Circulation (2017)

Introduction: Guidelines for hypercoagulable state testing (HT) for patients with acute venous thromboembolism (VTE) are lacking. HT is costly, consumes resources, and is acquired commonly in the absence of supporting evidence for management. The role of specific clinical factors in driving HT for patients with VTE is unknown. Hypothesis: We hypothesized that the characteristics of VTE subjects who had HT and those who did not have HT do not follow current recommendations. Methods: Subjects with VTE were identified from Vanderbilt’s Research Derivative, a repository of integrated clinical data derived from the EHR, using ICD codes, imaging study CPT codes, and anticoagulant use within a specific time frame. We defined HT as measurement of at least one of the following: lupus anticoagulant, anti-cardiolipin antibodies, antithrombin III deficiency, factor V Leiden, and protein C and S activity. Provoked events were defined as presence of one or more of the following: hospitalization within 90 days of VTE, l...
Abstract 13824: Oral Anticoagulants and Risk of Liver Injury in Patients With Atrial Fibrillation: A Prospective Study
Authors: Alvaro Alonso, Richard F MacLehose, Lin Y Chen, Lindsay G Bengtson, Alanna M Chamberlain, Faye L Norby, Pamela L Lutsey
Journal: Circulation (2016)

Introduction: Isolated cases of liver injury associated with the use of non-vitamin K antagonist oral anticoagulants (NOACs) have been reported. However, the comparative incidence of liver injury in users of different oral anticoagulants is unknown. Methods: We studied 113,717 patients (mean age 70, 39% women) with non-valvular atrial fibrillation (AF) included in the MarketScan® Commercial and Medicare Supplemental databases with a first prescription for oral anticoagulation after November 4, 2011, followed through December 31, 2014. Of these, 56,879 initiated warfarin, 17,286 initiated dabigatran, 30,347 initiated rivaroxaban, and 9,205 initiated apixaban. Liver injury hospitalizations were identified using selected inpatient diagnostic codes. Multivariable Cox models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) of liver injury by anticoagulant type. Results: During a median follow-up of 12 months, 960 hospitalizations with liver injury were identified. Rates of liver injury hospitalization (per 1000 person-years) by oral anticoagulant were 9.0 (warfarin), 4.0 (dabigatran), 6.6 (rivaroxaban), and 5.6 (apixaban). After multivariable adjustment, rates of liver injury hospitalization were lower in initiators of NOACs compared to warfarin: HR (95%CI) of 0.57 (0.46, 0.71), 0.88 (0.75, 1.03) and 0.70 (0.50, 0.97) for initiators of dabigatran, rivaroxaban, and apixaban, respectively (Table). Compared to dabigatran initiators, rivaroxaban initiators had a 56% increased risk of liver injury hospitalization (HR 1.56, 95%CI 1.22, 1.99). In addition to type of anticoagulant, prior liver, gallbladder, and kidney disease, cancer, anemia, heart failure, and alcoholism significantly predicted liver injury hospitalization. Conclusions: Among patients with non-valvular AF, NOACs were associated with lower risk of liver injury hospitalization compared to warfarin, with dabigatran showing the lowest risk.
Abstract 19207: Altered Cardiac Energetics and Impaired Sympathetic Activity in Patients With Right Ventricular Failure
Authors: Ali Ahmadi, Jennifer M Renaud, Steven Promislow, Ian Burwash, Girish Dwivedi, Jason Zelt, Robert A deKemp, Rob S Beanlands, Lisa M Mielniczuk
Journal: Circulation (2017)

Introduction: Reduced left ventricular (LV) myocardial efficiency (myocardial work per O2 (MVO2)) and increased sympathetic nervous (SN) activity have been associated with the failing LV. Less is known regarding the right heart. We hypothesized that patients (pts) with RV dysfunction demonstrate increased MVO2 suggesting altered RV energetics and increased SN activity which relate to patient outcomes. Methods: 31 pts with LV systolic dysfunction and NYHA class II or III previously studied to measure LV parameters, were assessed for RV function and size using echocardiography. PET imaging was used to measure RV oxidative metabolism (11C-acetate clearance rate (kmono)) and SN function (11C-Hydroxyephedrine (HED) standard uptake values (SUVs) where decreased HED indicates increased SN activity). MVO2 was extrapolated from the linear relationship of MVO2 to kmono for the LV. Time to first cardiac event (FCE) (hospitalization for heart failure, worsening functional class, arrhythmia, heart transplantation and ...
Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
Authors: Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang, Huai-Xiang Hao, Angela Tam, Hui Qin Wang, Jinsheng Liang, Matthew T. DiMare, Hyo-Eun Carrie Bhang, Youzhen Wang, Pascal Furet, William R. Sellers, Francesco Hofmann, Joseph Schoepfer, Ralph Tiedt
Journal: Clinical Cancer Research (2019)

Abstract Purpose: The selective MET inhibitor capmatinib is being investigated in multiple clinical trials, both as a single agent and in combination. Here, we describe the preclinical data of capmatinib, which supported the clinical biomarker strategy for rational patient selection. Experimental Design: The selectivity and cellular activity of capmatinib were assessed in large cellular screening panels. Antitumor efficacy was quantified in a large set of cell line– or patient-derived xenograft models, testing single-agent or combination treatment depending on the genomic profile of the respective models. Results: Capmatinib was found to be highly selective for MET over other kinases. It was active against cancer models that are characterized by MET amplification, marked MET overexpression, MET exon 14 skipping mutations, or MET activation via expression of the ligand hepatocyte growth factor (HGF). In cancer models where MET is the dominant oncogenic driver, anticancer activity could be further enhanced by combination treatments, for example, by the addition of apoptosis-inducing BH3 mimetics. The combinations of capmatinib and other kinase inhibitors resulted in enhanced anticancer activity against models where MET activation co-occurred with other oncogenic drivers, for example EGFR activating mutations. Conclusions: Activity of capmatinib in preclinical models is associated with a small number of plausible genomic features. The low fraction of cancer models that respond to capmatinib as a single agent suggests that the implementation of patient selection strategies based on these biomarkers is critical for clinical development. Capmatinib is also a rational combination partner for other kinase inhibitors to combat MET-driven resistance.
Blinded by the light: a nonhuman primate model of achromatopsia
Authors: Katherine E. Uyhazi, Jean Bennett
Journal: Journal of Clinical Investigation (2019)

Achromatopsia is an inherited retinal degeneration characterized by the loss of cone photoreceptor function. In this issue of the JCI, Moshiri et al. characterize a naturally occurring model of the disease in the rhesus macaque caused by homozygous mutations in the phototransduction enzyme PDE6C. Using retinal imaging, and electrophysiologic and biochemical methods, the authors report a clinical phenotype nearly identical to the human condition. These findings represent the first genetic nonhuman primate model of an inherited retinal disease, and provide an ideal testing ground for the development of novel gene replacement, gene editing, and cell replacement therapies for cone dystrophies.
Self-expandable metal stent in lumen-apposing metal stent (the SEMS-in-LAMS procedure): a simple salvage procedure after LAMS misplacement
Authors: Marcos Lera, Sérgio Matuguma, Antonio Madruga-Neto, Vitor Brunaldi, Maurício Minata, Hugo Guedes, Eduardo de Moura
Journal: Endoscopy (2019)

Lumen-apposing metal stents (LAMSs) have been widely used for drainage of pancreatic fluid collections (PFCs) [1]. However, misplacement of stents is not rare and demands immediate intervention. We describe the use of a biliary self-expandable metal stent (SEMS) placed through the LAMS to address misplacement during an endoscopic ultrasound (EUS)-guided drainage procedure.
A Simple Geriatric Vulnerability Index for Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Authors: Richard J Lin, Theresa A Elko, Sean M Devlin, Ann A. Jakubowski, Armin Shahrokni, Parastoo B. Dahi, Miguel-Angel Perales, Roni Tamari, Brian C. Shaffer, Craig S. Sauter, Esperanza B. Papadopoulos, H.R. Castro-Malaspina, Juliet Barker, Molly Maloy, Beatriz Korc-Grodzicki, Sergio Giralt
Journal: Blood (2018)
Administration of anti-IgE to pregnant mice caused IgE-class-specific immunosuppression in offspring
Authors: Hideaki Morita, Masato Tamari, Masako Fujiwara, Kenichiro Motomura, Yasuhiko Koezuka, Go Ichien, Kenji Matsumoto, Kimishige Ishizaka, Hirohisa Saito
Journal: Journal of Allergy and Clinical Immunology (2019)
A new clinically based staging system for gallbladder cancer.
Authors: Siddhartha Yadav, Kritika Prasai, Mohamed Mady, Mohamed Abdelrahim Muddathir Hassan, Lewis R. Roberts, Amit Mahipal
Journal: Journal of Clinical Oncology (2019)

433 Background: Current staging systems for gallbladder cancer (GBC) are inadequate, as they are based on surgical pathology, and therefore are not relevant for unresectable patients and patients undergoing neoadjuvant chemotherapy. Methods: Patients with a confirmed diagnosis of GBC who were seen at Mayo Clinic between the years 2000 and 2016 were included in this analysis. Data on demographic and tumor characteristics and outcomes were collected by retrospective review of electronic medical records. A model predictive of overall survival was developed using Cox proportional hazard regression analysis. Harrel’s C-statistic was calculated to evaluate the predictive accuracy of the model and compared with the TNM staging system. Results: A total of 523 patients were included in the final analysis, with a median age of diagnosis of 68 years. The median duration of follow up of the entire cohort was 12 months. In multivariate analysis, factors predictive of poorer overall survival were: ages 65-74 years (HR : 1.80, 95% CI: 1.33–2.43) and ages 75+ years (HR: 2.93, 95% CI: 2.12–4.06) compared to age &lt;55 years; tumor size ≥ 5 cm by imaging (HR: 1.24, 95% CI: 1.01–1.55); nodal involvement by imaging (HR:1.61, 95% CI: 1.23–2.10); involvement of distant organs by imaging (HR: 2.85, 95% CI: 2.16–3.75); ECOG performance score of 2 or higher (HR: 1.78, 95% CI: 1.36–2.32) compared to ECOG 0-1; albumin level &lt;3.5 g/dL (HR: 1.40, 95% CI: 1.08–1.81); and alkaline Phosphatase level ≥ 200 IU/L (HR: 1.49, 95% CI: 1.21–1.84). Using these seven predictive factors of survival we created a four-tier staging system. The median survivals of Stages I, II, III and IV created in our novel system were 64, 34, 20 and 7 months with corresponding hazard ratios of 1, 1.5, 2.5 and 8.5 respectively. The C-statistic for this novel staging system was 0.68 compared to C-statistic of 0.69 for the TNM staging system, indicating similar performance in predicting survival. Conclusions: We have created a novel clinically-based staging system for patients with GBC based on nonoperative information at the time of diagnosis which performs on par with the current surgical pathology based TNM staging system.
Abstract 14387: Pulmonary Vein Antrum Isolation in Patients With Paroxysmal Atrial Fibrillation: a Decade of Follow-Up
Authors: Pasquale Santangeli, Luigi Di Biase, Francesco Santoro, Rong Bai, J. David Burkhardt, Rodney Horton, Javier Sanchez, Shane Bailey, Richard Hongo, Salwa Beheiry, Andrea Natale
Journal: Circulation (2013)

Introduction: Pulmonary vein antrum isolation (PVAI) is the cornerstone of current catheter-based therapies for paroxysmal atrial fibrillation (AF). Data on very long-term follow-up of PVAI are lim...
Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib
Authors: Jan A. Burger
Journal: Clinical Cancer Research (2019)

Abstract Continuous B-cell receptor (BCR) stimulation by antigens in secondary lymphoid tissues is a key pathogenic mechanism in chronic lymphocytic leukemia (CLL). Therapy with ibrutinib mobilizes tissue CLL cells into the peripheral blood (PB), away from tissue antigen. Consequently, mobilized antigen-deprived CLL cells upregulate surface immunoglobulin M (IgM), providing robust evidence for this mechanism of pathogenesis. See related article by Drennan et al., p. 2503
Co-delivery of miR-181a and melphalan by lipid nanoparticles for treatment of seeded retinoblastoma
Authors: Seyed Nasrollah Tabatabaei, Rabeb Mouna Derbali, Chun Yang, Rosanne Superstein, Patrick Hamel, Jeanne Leblond Chain, Pierre Hardy
Journal: Journal of Controlled Release (2019)

Melphalan is an efficient chemotherapeutic agent that is currently used to treat retinoblastoma (Rb); however, the inherent risk of immunogenicity and the hazardous integration of this drug in healthy cells is inevitable. MicroRNAs are short non-coding single-stranded RNAs that affect a vast range of biological processes. Previously, we focused on the regulatory role of miR-181a during cancer development and progression. In this manuscript, 171 nm switchable lipid nanoparticles (LNP) co-delivered melphalan and miR-181a with encapsulation efficiencies of 93%. Encapsulation of melphalan in LNP significantly improved its therapeutic efficiency. Gene analysis shows that miR-181a decreases the expression of anti-proliferative gene MAPK1 and anti-apoptotic gene Bcl-2, but significantly increased the expression of pro-apoptotic gene BAX. Our results suggest that the two agents have a complementary effect in reducing the viability of cultured Rb cells (primary and cell line) and decreasing Rb cell counts in an in-vivo xenograft Rb model in rats. Our results suggest that the proposed co-delivery technique significantly increases the therapeutic impact, allows for lower administration of melphalan, and consequently, could minimize the cytotoxic side-effects of this drug.
Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid
Authors: Hideaki Morita, Terufumi Kubo, Beate Rückert, Avinash Ravindran, Michael B. Soyka, Arturo Ottavio Rinaldi, Kazunari Sugita, Marcin Wawrzyniak, Paulina Wawrzyniak, Kenichiro Motomura, Masato Tamari, Keisuke Orimo, Naoko Okada, Ken Arae, Kyoko Saito, Can Altunbulakli, Francesc Castro-Giner, Ge Tan, Avidan Neumann, Katsuko Sudo, Liam O'Mahony, Kenya Honda, Susumu Nakae, Hirohisa Saito, Jenny Mjösberg, Gunnar Nilsson, Kenji Matsumoto, Mübeccel Akdis, Cezmi A. Akdis
Journal: Journal of Allergy and Clinical Immunology (2019)
Neutrophil and eosinophil recruitment in alveolar wall induced by capsaicin, substance P and neurokinin a in guinea pigs
Authors: I. de F. L. C. Tiberio, E. A. Leick Maldonado, L. Miyadahira, G. Spilborghs, D. I. Kasahara, Mílton de Arruda Martins
Journal: American Journal of Respiratory and Critical Care Medicine (2000)
Pityriasis rubra pilaris: A study evaluating patient quality of life in 2 populations
Authors: A. Brooke Eastham, Elizabeth Y. Tkachenko, Alisa N. Femia, Lisa K. Pappas-Taffer, Misha Rosenbach, Cara J. Joyce, Stephanie Liu, Ruth Ann Vleugels
Journal: Journal of the American Academy of Dermatology (2019)
Optimized Induction of Mitochondrial Apoptosis By Combination Therapies with Venetoclax for Chemotherapy-Free Treatment of BCR-ABL+ Acute Lymphoblastic Leukemia in Preclinical Models
Authors: Matthias Eder, Hanna Kirchhoff, Karin Battmer, Katharina Wohlan, Melanie Ricke-Hoch, Sergej Erschow, Edward Law, Arnold Kloos, Michael Heuser, Arnold Ganser, Denise Hilfiker-Kleiner, Olaf Heidenreich, Michaela Scherr
Journal: Blood (2018)
The Evolution of Endovascular Treatment for Traumatic Thoracic Aortic Injury
Authors: Nicholas Osborne, Danielle Christine Sutzko
Journal: JAMA Network Open (2019)

Yu-Ting Cheng, MD; Chi-Tung Cheng, MD; Shang-Yu Wang, MD; Victor Chien-Chia Wu, MD; Pao-Hsien Chu, MD, FESC; An-Hsun Chou, MD, PhD; Ching-Chang Chen, MD; Po-Jen Ko, MD; Kuo-Sheng Liu, MD, PHD; Shao-Wei Chen, MD
Abstract B073: Stat5a/b blockade sensitizes prostate cancer to radiation through inhibition of Rad51 and DNA repair
Authors: Cristina Maranto, Vindhya Udhane, Ayush Dagvadorj, David T. Hoang, Lei Gu, Vitali Alexeev, Kareem Malas, Karmel Cardenas, Mateusz Koptyra, Jonathan R. Brody, Ulrich Rodeck, Carmen Bergom, Ken A. Iczkowski, Ken Jacobsohn, William See, Sara M. Schmitt, Marja T. Nevalainen
Journal: Cancer Research (2018)

Abstract Purpose: The standard treatment for organ-confined prostate cancer (PC) is surgery or radiation, and locally advanced PC is typically treated with radiotherapy alone or in combination with androgen-deprivation therapy. Here, we investigated whether Stat5a/b participates in regulation of double-strand DNA break repair in PC, and if Stat5 inhibition may provide a novel strategy to sensitize PC to radiation therapy. Experimental Design: Stat5a/b regulation of DNA repair in PC was evaluated by comet assay and clonogenic survival assay, followed by assays specific to homologous recombination (HR) DNA repair and nonhomologous end-joining (NHEJ) DNA repair. For HR DNA repair, Stat5a/b regulation of Rad51 and the mechanisms underlying the regulation were investigated in PC cells, xenograft tumors, and patient-derived PCs ex vivo in 3D explant cultures. Stat5a/b induction of Rad51 and HR DNA repair and responsiveness to radiation were evaluated in vivo in mice bearing PC xenograft tumors. Results: Stat5a/b is critical for Rad51 expression in PC via Jak2-dependent mechanisms by inducing Rad51 mRNA levels. Consistent with this, genetic knockdown of Stat5a/b suppressed HR DNA repair while not affecting NHEJ DNA repair. Pharmacologic Stat5a/b inhibition potently sensitized PC cell lines and PC tumors to radiation, while not affecting radiation sensitivity of the neighboring tissues. Conclusion: This work introduces a novel concept of a pivotal role of Jak2-Stat5a/b signaling for Rad51 expression and HR DNA repair in PC. Inhibition of Jak2-Stat5a/b signaling sensitizes PC to radiation and, therefore, may provide an adjuvant therapy for radiation to reduce radiation-induced damage to the neighboring tissues. Citation Format: Cristina Maranto, Vindhya Udhane, Ayush Dagvadorj, David T. Hoang, Lei Gu, Vitali Alexeev, Kareem Malas, Karmel Cardenas, Mateusz Koptyra, Jonathan R. Brody, Ulrich Rodeck, Carmen Bergom, Ken A. Iczkowski, Ken Jacobsohn, William See, Sara M. Schmitt, Marja T. Nevalainen. Stat5a/b blockade sensitizes prostate cancer to radiation through inhibition of Rad51 and DNA repair [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr B073.
Abstract 15357: Using Biometric Analysis to Identify Patient Characteristics Which Affect the Quality of Cardiopulmonary Resuscitation
Authors: Birju R Rao, Chris M Kapp, Jennifer M Loeb, John Birchak, Maria Nehmer, Travis T Yamanaka, Amer K Ardati, Dustin R Fraidenburg
Journal: Circulation (2016)

Introduction: In-hospital cardiac arrest is a source of significant morbidity and mortality, with survival to discharge as low as 11%. Cardiopulmonary resuscitation (CPR) guidelines have focused on...
Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial
Authors: Lihua Budde, Joo Y Song, Young Kim, Suzette Blanchard, Jamie Wagner, Anthony S. Stein, Lihong Weng, Marissa Del Real, Rochelle Hernandez, Emanuela Marcucci, Jennifer K Shepphird, Xiuli Wang, Brent Wood, Guido Marcucci, Christine E Brown, Stephen J. Forman
Journal: Blood (2017)
Abstract 18669: Differences Between Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement on Cardiac Energetics
Authors: Yoshiyuki Yamashita, Yoshihisa Tanoue, Tomoki Ushijima, Hiromichi Sonoda, Yasuhisa Oishi, Kazuhiro Hinokiyama, Hideki Tatewaki, Akira Shiose
Journal: Circulation (2017)

Introduction: TAVR is an established therapy for high-risk patients with severe aortic stenosis. The effects of TAVR on cardiac energetics have not been described. We compared changes in cardiac en...
Abstract 10419: Identification of High-Risk Atherosclerotic Plaques in Patients With Moderate Carotid Artery Stenosis by Combined F-18 Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography
Authors: Georgios Christopoulos, Martin Rodriguez-Porcel, Alejandro A Rabinstein, Brad Kemp, Philip A Araoz, Val Lowe, Panithaya Chareonthaitawee
Journal: Circulation (2018)

Background: F-18 positron emission tomography (PET) may be used to identify low-grade carotid artery inflammation (Figure 1). Objective: We sought to investigate the association between cerebrovasc...
Abstract 11900: Influence of Competing Risks on the Association Between Warfarin and Ischemic Stroke in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
Authors: Jeffrey M Ashburner, Alan S Go, Yuchiao Chang, Margaret C Fang, Lisa Fredman, Katie M Applebaum, Daniel E Singer
Journal: Circulation (2015)

Introduction: Studies examining the association between warfarin therapy and incidence of ischemic stroke in adults with atrial fibrillation (AF) have not accounted for patients who die of non-stroke causes. Hypothesis: Accounting for the competing risk of death may provide greater understanding of the “real world” impact of warfarin on stroke risk during multiyear follow-up in a large, diverse cohort of AF patients. Methods: We assessed this association in the ATRIA community-based cohort of AF patients (n=13,559; study years 1996-2003), with thromboembolic (&gt;90% ischemic stroke) events (TEE) being clinician-adjudicated. Extended Cox proportional hazards regression with time-varying warfarin exposure estimated the cause-specific hazard ratio (HR) for TEE while adjusting for stroke risk factors. Fine and Gray subdistribution regression was used to estimate this association while also accounting for competing death events. Results: Patients using warfarin were younger, more likely to have had a prior stroke, and to have known diabetes, coronary disease, and heart failure, and also had higher mean CHA2DS2VASc scores (3.68 vs. 3.22). The death rate was much higher in the non-warfarin group (8.1 deaths/100 person-years; 2637 deaths vs. 5.5 deaths/100 person-years; 1777 deaths on warfarin). The cause-specific HR indicated a large reduction in TE with warfarin use (adjusted HR: 0.57, 95% CI: 0.50-0.65). In subdistribution hazard models accounting for competing death events over the full follow-up of 6 years, this association was substantially attenuated (adjusted HR: 0.87, 95% CI: 0.77-0.99). In analyses limited to 1-year follow-up with only 648 competing death events, the results without accounting for competing risks (adjusted cause-specific HR: 0.55, 95% CI: 0.43-0.71) were similar to the results that did account for competing risks (adjusted subdistribution HR: 0.59, 95% CI: 0.46-0.75). Conclusions: By accounting for competing death events, our results reflect a more realistic estimate of the multi-year stroke prevention benefits of warfarin for patients with AF. Many old/frail individuals with AF will not live long enough to gain substantial benefit from warfarin.
SERIAL ANALYSIS OF THE MALAPPOSED AND UNCOVERED STRUTS OF THE NEW GENERATION OF EVEROLIMUS-ELUTING BIORESORBABLE SCAFFOLD USING OPTICAL COHERENCE TOMOGRAPHY
Authors: Josep Gomez-Lara, Maria D. Radu, Salvatore Brugaletta, Vasim Farooq, Roberto Diletti, Stefan Windecker, Robert Whitbourn, Dariusz Dudeck, Pieter C. Smits, Evelyn Regar, Hector M. Garcia-Garcia, Patrick Serruys
Journal: Journal of the American College of Cardiology (2011)